Australien - engelska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dechra veterinary products (australia) pty. ltd. - amoxycillin as amoxycillin trihydrate; clavulanic acid (as potassium salt) - oral tablet - amoxycillin as amoxycillin trihydrate antibiotic active 400.0 mg/tb; clavulanic acid (as potassium salt) antibiotic active 100.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - antibiotics - oral, parenteral | bacterial infection | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | associated with viral disease | avian mycoplasmas | clavulanic acid sensitive | coccidiosis | coryza | crd | dermatoses | diarrhoea | endometritis | enteritis | enzootic pneumonia | escherichia coli | european brood disease | gentamicin sensitive | gram negative organisms | gram positive organisms | hypermotility | infected wounds | infections | lactating | mastitis | post parturient bacterial infe | primary bacterial infection | protozoal infections | pyometra | salmonellosis | sinusitis | sulfadiazine sensitive bacteri | systemic bacterial infection | trimethoprim sensitive bacteri | tylosin sensitive bacteria

Malta - engelska - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - clavulanic acid, amoxicillin sodium - powder for solution for infusion or injection - amoxicillin sodium 1000 mg clavulanic acid 200 mg - antibacterials for systemic use

Malta - engelska - Medicines Authority

generics uk limited station close, potters bar, herts, en6 1tl, united kingdom - amoxicillin, clavulanic acid - film-coated tablet - amoxicillin 250 mg clavulanic acid 125 mg - antibacterials for systemic use

Australien - engelska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amoxicillin trihydrate, quantity: 1004 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 148.9 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; purified talc; hypromellose; microcrystalline cellulose; titanium dioxide; macrogol 6000; sodium starch glycollate; propylene glycol - amoxicillin and clavulanic acid tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms: - urinary tract infections (uncomplicated and complicated). - lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. - upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. - skin and skin structure infections. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxyclave duo scp and amoxyclave duo forte scp tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxyclave duo scp and amoxyclave duo forte scp tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 148.9 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; methylcellulose; dimeticone 100; colloidal anhydrous silica; purified talc; magnesium stearate; titanium dioxide; sodium starch glycollate; diethyl phthalate - amoxicillin and clavulanic acid tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms: - urinary tract infections (uncomplicated and complicated). - lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. - upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. - skin and skin structure infections. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxyclave duo scp and amoxyclave duo forte scp tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxyclave duo scp and amoxyclave duo forte scp tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Malta - engelska - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - amoxicillin, clavulanic acid - film-coated tablet - clavulanic acid 125 mg amoxicillin 250 mg - antibacterials for systemic use

Malaysia - engelska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

komedic sdn bhd - clavulanic acid; amoxycillin -

Irland - engelska - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - amoxicillin sodium; potassium clavulanate - powder for solution for injection/infusion - 500 mg/100 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

Irland - engelska - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - amoxicillin sodium; potassium clavulanate - powder for solution for injection/infusion - 1000 mg/200 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

Irland - engelska - HPRA (Health Products Regulatory Authority)

brown & burk uk ltd - amoxicillin; clavulanic acid - powder for oral suspension - 400/57 mg/5ml - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor